1. Home
  2. KELYB vs ARVN Comparison

KELYB vs ARVN Comparison

Compare KELYB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc. Class B

KELYB

Kelly Services Inc. Class B

N/A

Current Price

$18.00

Market Cap

551.2M

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.04

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KELYB
ARVN
Founded
1946
2015
Country
United States
United States
Employees
4900
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
551.2M
658.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
KELYB
ARVN
Price
$18.00
$8.04
Analyst Decision
Buy
Analyst Count
0
19
Target Price
N/A
$15.05
AVG Volume (30 Days)
2.6K
680.3K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
1.95%
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
N/A
$262,600,000.00
Revenue This Year
$0.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.38
$6.06
52 Week High
$125.00
$14.22

Technical Indicators

Market Signals
Indicator
KELYB
ARVN
Relative Strength Index (RSI) 50.27 46.65
Support Level $11.66 $7.35
Resistance Level $18.11 $10.18
Average True Range (ATR) 0.86 0.41
MACD -0.18 0.17
Stochastic Oscillator 43.37 70.20

Price Performance

Historical Comparison
KELYB
ARVN

About KELYB Kelly Services Inc. Class B

Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: